|
1
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teaque J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lovly CM, Dahlman KB, Fohn LE, Su Z,
Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, et
al: Routine multiplex mutational profiling of melanomas enables
enrollment in genotype-driven therapeutic trials. PLoS One.
7:e353092012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jakob JA, Bassett RL Jr, Ng CS, Curry JL,
Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim
KB, et al: NRAS mutation status is an independent prognostic factor
in metastatic melanoma. Cancer. 118:4014–4023. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gray-Schopfer VC, Karasarides M, Hayward R
and Marais R: Tumor necrosis factor-α blockes apoptosis in melanoma
cells when BRAF signaling is inhibited. Cancer Res. 67:122–129.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Testori A,
et al: Improved survival with vemurafenib in melanoma with BRAF
V600E mutation. N Eng J Med. 364:2507–2516. 2011. View Article : Google Scholar
|
|
6
|
Hauschild A, Grob JJ, Demidov LV, Jouary
T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr,
Kaempgen E, et al: Dabrafenib in BRAF-mutated metastatic melanoma:
A multicentre, open-label, phase 3 randomised controlled trial.
Lancet. 380:358–365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lito P, Rosen N and Solit DB: Tumor
adaptation and resistance to RAF inhibitors. Nat Med. 21:1401–1409.
2013. View
Article : Google Scholar
|
|
8
|
Falchook GS, Lewis KD, Infante JR, Gordon
MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT,
et al: Activity of the oral MEK inhibitor trametinib in patients
with advanced melanoma: A phase 1 dose-escalation trial. Lancet
Oncol. 13:782–789. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shimizu T, Tolcher AW, Papadopoulos KP,
Beeram M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, Kaiser B,
et al: The clinical effect of the dual-targeting strategy involving
PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced
cancer. Clin Cancer Res. 18:2316–2325. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Taha TA, Hannun YA and Obeid LM:
Sphingosine kinase: Biochemical and cellular regulation and role in
disease. J Biochem Mol Biol. 39:113–131. 2006.PubMed/NCBI
|
|
11
|
Ogretmen B and Hannun YA: Biologically
active sphingolipids in cancer pathogenesis and treatment. Nat Rev
Cancer. 4:604–616. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Olivera A, Kohama T, Edsall L, Nava V,
Cuvillier O, Poulton S and Spiegel S: Sphingosine kinase expression
increases intracellular sphingosine-1-phosphate and promotes cell
growth and survival. J Cell Biol. 147:545–558. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xia P, Wang L, Gamble JR and Vadas MA:
Activation of sphingosine kinase by tumor necrosis factor-alpha
inhibits apoptosis in human endothelial cells. J Biol Chem.
274:34499–34505. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Spiegel S and Milstien S:
Sphingosine-1-phosphate: An enigmatic signalling lipid. Nat Rev Mol
Cell Biol. 4:397–407. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xia P, Gamble JR, Wang L, Pitson SM,
Moretti PA, Wattenberg BW, D'Andrea RJ and Vedas MA: An oncogenic
role of sphingosine kinase. Curr Biol. 10:1527–1530. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ho JW, Man K, Sun CK, Lee TK, Poon RT and
Fan ST: Effects of a novel immunomodulating agent, FTY720, on tumor
growth and angiogenesis in hepatocellular carcinoma. Mol Cancer
Ther. 4:1430–1438. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pchejetski D, Doumerc N, Golzio M, Naymark
M, Teissié J, Kohama T, Waxman J, Malavaud B and Cuvillier O:
Chemosensitizing effects of sphingosine kinase-1 inhibition in
prostate cancer cell and animal models. Mol Cancer Ther.
7:1836–1845. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
French KJ, Schrecengost RS, Lee BD, Zhuang
Y, Smith SN, Eberly JL, Yun JK and Smith CD: Discovery and
evaluation of inhibitors of human sphingosine kinase. Cancer Res.
63:5962–5969. 2003.PubMed/NCBI
|
|
19
|
Shida D, Takabe K, Kapitonov D, Milstien S
and Spiegel S: Targeting SphK1 as a new strategy against cancer.
Curr Drug Targets. 9:662–673. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vadas M, Xia P, McCaughan G and Gamble J:
The role of sphingosine kinase 1 in cancer: Oncogene or
non-oncogene addiction? Biochim Biophys Acta. 1781:442–447. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Azuma H, Takahara S, Horie S, Muto S,
Otsuki Y and Katsuoka Y: Induction of apoptosis in human bladder
cancer cells in vitro and in vivo caused by FTY720 treatment. J
Urol. 169:2372–2377. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ubai T, Azuma H, Kotake Y, Inamoto T,
Takahara K, Ito Y, Kiyama S, Sakamoto T, Horie S, Muto S, et al:
FTY720 induced Bcl-associated and Fas-independent apoptosis in
human renal cancer cells in vitro and significantly reduced in vivo
tumor growth in mouse xenograft. Anticancer Res. 27:75–88.
2007.PubMed/NCBI
|
|
23
|
Billich A, Bornancin F, Dévay P,
Mechtcheriakova D, Urtz N and Baumruker T: Phosphorylation of the
immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem.
278:47408–47415. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Paugh SW, Payne SG, Barbour SE, Milstien S
and Spiegel S: The immunosuppressant FTY720 is phosphorylated by
sphingosine kinase type2. FEBS Lett. 554:189–193. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang JD, Takahara S, Nonomura N, Ichimaru
N, Toki K, Azuma H, Matsumiya K, Okuyama A and Suzuki S: Early
induction of apoptosis in androgen-independent prostate cancer cell
line by FTY720 requires caspase-3 activation. Prostate. 40:50–55.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Matloubian M, Lo CG, Cinamon G, Lesneski
MJ, Xu Y, Brinkmann V, Allende ML, Proia RL and Cyster JG:
Lymphocyte egress from thymus and peripheral lymphoid organs is
dependent on S1P receptor 1. Nature. 427:355–360. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pereira FV, Arruda DC, Figueiredo CR,
Massaoka MH, Matsuo AL, Bueno V and Rodrigues EG: FTY720 induces
apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic
development in vivo, and modulates the immune system. Clinics (Sao
Paulo). 68:1018–1027. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
LaMontagne K, Littlewood-Evans A, Schnell
C, O'Reilly T, Wyder L, Sanchez T, Probst B, Butler J, Wood A, Liau
G, et al: Antagonism of sphingosine-1-phosphate receptors by FTY720
inhibits angiogenesis and tumor vascularization. Cancer Res.
66:221–231. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tonelli F, Lim KG, Loveridge C, Long J,
Pitson SM, Tigyi G, Bittman R, Pyne S and Pyne NJ: FTY720 and
(S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and
promote its proteasomal degradation in human pulmonary artery
smooth muscle, breast cancer and androgen-independent prostate
cancer cells. Cell Signal. 22:1536–1542. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kihara Y, Maceyka M, Spiegel S and Chun J:
Lysophospholipid receptor nomenclature review: IUPHAR review 8. Br
J Pharmacol. 171:3575–3594. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang N, Qi Y, Wadham C, Wang L, Warren A,
Di W and Xia P: FTY720 induces necrotic cell death and autophagy in
ovarian cancer cells: A protective role of autophagy. Autophagy.
6:1157–1167. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Azuma H, Takahara S, Ichimaru N, Wang JD,
Itoh Y, Otsuki Y, Morimoto J, Fukui R, Hoshiga M, Ishihara T, et
al: Marked prevention of tumor growth and metastasis by a novel
immunosuppressive agent, FTY720, in mouse breast cancer models.
Cancer Res. 62:1410–1419. 2002.PubMed/NCBI
|
|
33
|
Chua CW, Lee DT, Ling MT, Zhou C, Man K,
Ho J, Chan FL, Wang X and Wong YC: FTY720, a fungus metabolite,
inhibits in vivo growth of andorogen-independent prostate cancer.
Int J Cancer. 117:1039–1048. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ishitsuka A, Fujine E, Mizutani Y, Tawada
C, Kanoh H, Banno Y and Seishima M: FTY720 and cisplatin
synergistically induce cell death of cisplatin-resistant melanoma
cells through downregulation of PI3K pathway and decrease in
epidermal growth factor receptor expression. Int J Mol Med.
34:1169–1174. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Stordal BK, Davey MW and Davey RA:
Oxaliplatin induces drug resistance more rapidly than cisplatin in
H69 small cell lung cancer cells. Cancer Chemother Pharmacol.
58:256–265. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Meier F, Schittek B, Busch S, Garbe C,
Smalley K, Satyamoorthy K, Li G and Herlyn M: The RAS/RAF/MEK/ERK
and PI3K/AKT signaling pathways present molecular targets for the
effective treatment of advanced melanoma. Front Biosci.
10:2986–3001. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sinnberg T, Lasithiotakis K, Niessner H,
Schittek B, Flaherty KT, Kulms D, Maczey E, Campos M, Gogel J,
Garbe C and Meier F: Inhibition of PI3K-AKT-mTOR signaling
sensitizes melanoma cells to cisplatin and temozolomide. J Invest
Dematol. 129:1500–1515. 2009. View Article : Google Scholar
|
|
38
|
Nazarian R, Shi H, Wang Q, Kong X, Koya
RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al: Melanoma
acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS
upregulation. Nature. 468:973–977. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Villanueva J, Vultur A, Lee JT,
Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu
X, Gimotty PA, Kee D, et al: Acquired resistance to BRAF inhibitors
mediated by a RAF kinase switch in melanoma can be overcome by
cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 18:683–695. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Johannessen CM, Boehm JS, Kim SY, Thomas
SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP,
Barretina J, et al: COT drives resistance to RAF inhibition through
MAP kinase pathway reactivation. Nature. 468:968–972. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Emery CM, Vijayendran KG, Zipser MC,
Sawyer AM, Niu L, Kim JJ, Hatton C, Chapra R, Oberholzer PA,
Karpova MB, et al: MEK1 mutations confer resistance to MEK and
B-RAF inhibition. Proc Natl Acad Sci USA. 106:20411–20416. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hodis E, Watson IR, Kryukov GV, Arold ST,
Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C,
et al: A landscape of driver mutations in melanoma. Cell.
150:251–263. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Patmanathan SN, Yap LF, Murray PG and
Paterson IC: The antineoplastic properties of FTY720: Evidence for
the repurposing of fingolimod. J Cell Mol Med. 19:2329–2340. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Filoni A, Lospalluti L, Giudice G,
Bonamonte D and Vestita M: Fingolimod and melanoma risk: Is there
sufficient evidence? Clin Exp Dermatol. 42:427–428. 2017.
View Article : Google Scholar
|
|
45
|
Haebich G, Mughal A and Tofazzal N:
Superficial spreading malignant melanoma in a patiet on fingolimod
therapy for multiple sclerosis. Clin Exp Dermatol. 41:433–434.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Conzett KB, Kolm I, Jelcic I, Kamarachev
J, Dummer R, Braun R, French LE, Linnebank M and Hofbauer GF:
Melanoma occurring during treatment with fingolimod for multiple
sclerosis: a case report. Arch Dermatol. 147:991–992. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jain A, Tripathi R, Turpin CP, Wanq C and
Pattner R: Abl kinase regulation by BRAF/ERK and cooporation with
Akt in melanoma. Oncogene. 36:4585–4596. 2017. View Article : Google Scholar : PubMed/NCBI
|
